In April 2026, the FDA removed BPC-157 from its Category 2 list (substances with safety concerns that were previously restricted from compounding)
The baseline HbA1c in the tirzepatide arms was 8.23%8.36% and 8.37% in the placebo group
By following a gradual titration process, most people experience milder side effects that either become manageable or disappear entirely as their body adjusts
In that context, theres been quite a buzz about the potential ability for GLP-1 receptor agonists to improve alcohol use, Dr

Key protective strategies include: Pre-treatment ophthalmologic evaluation : Establish baseline retinal status before initiating GLP-1 therapy, particularly in patients with diabetes duration exceeding 10 years or poor prior glycemic control Individualized medication titration : Consider a more gradual dose escalation approach to avoid precipitous drops in blood glucose for patients with advanced diabetic retinopathy, in coordination with ophthalmology care Appropriate monitoring : Discuss with your healthcare provider whether more frequent eye examinations are needed based on your individual risk factors and baseline retinal status Prompt reporting of visual symptoms : Contact your healthcare provider immediately if you experience sudden vision loss, new or dense floaters, flashing lights, a "curtain" over your vision, eye pain with vision changes, or any sudden vision disturbance Patients without pre-existing diabetic retinopathy can generally follow standard eye examination schedules and do not require additional ophthalmologic monitoring solely due to GLP-1 use
